dc.contributor.author | Merdrignac, Lore | |
dc.contributor.author | El Belghiti, Fatima Aït | |
dc.contributor.author | Pandolfi, Elisabetta | |
dc.contributor.author | Acosta, Lesly | |
dc.contributor.author | Fabiánová, Kateřina | |
dc.contributor.author | Habington, Adele | |
dc.contributor.author | García Cenoz, Manuel | |
dc.contributor.author | Bøås, Håkon | |
dc.contributor.author | Toubiana, Julie | |
dc.contributor.author | Tozzi, Alberto E. | |
dc.contributor.author | Jordan, Iolanda | |
dc.contributor.author | Zavadilová, Jana | |
dc.contributor.author | O'Sullivan, Niam | |
dc.contributor.author | Navascués, Ana | |
dc.contributor.author | Flem, Elmira | |
dc.contributor.author | Croci, Ilena | |
dc.contributor.author | Jané, Mireia | |
dc.contributor.author | Křížová, Pavla | |
dc.contributor.author | Cotter, Suzanne | |
dc.contributor.author | Fernandino, Leticia | |
dc.contributor.author | Bekkevold, Terese | |
dc.contributor.author | Muñoz-Almagro, Carmen | |
dc.contributor.author | Bacci, Sabrina | |
dc.contributor.author | Kramarz, Piotr | |
dc.contributor.author | Kissling, Esther | |
dc.contributor.author | Savulescu, Camelia | |
dc.contributor.author | Renacoq Group | |
dc.contributor.author | The PERTINENT Group | |
dc.date.accessioned | 2024-04-05T08:19:40Z | |
dc.date.available | 2024-04-05T08:19:40Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Merdrignac, Lore El Belghiti, Fatima Aït Pandolfi, Elisabetta [et al.]. Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019. Vaccine, 2024, 42(9), p. 2370-2379. Disponible en: <https://www.sciencedirect.com/science/article/pii/S0264410X2400272X?via%3Dihub>. Fecha de acceso: 5 abr. 2024. DOI: 10.1016/j.vaccine.2024.02.090 | ca |
dc.identifier.issn | 0264-410X | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/4186 | |
dc.description.abstract | Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36–73). Adjusted VE was 48 % (95 %CI: 5–71) for dose one (416 eligible infants) and 76 % (95 %CI: 43–90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. Conclusions: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three. | ca |
dc.format.extent | 9 | ca |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | ca |
dc.relation.ispartof | Vaccine | ca |
dc.relation.ispartofseries | 42;9 | |
dc.rights | © 2024 The Author(s). Published by Elsevier Ltd. | ca |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.other | Tos ferina | ca |
dc.subject.other | Vacuna contra la tos ferina | ca |
dc.subject.other | Efectivitat de la vacuna | ca |
dc.subject.other | Vigilància hospitalària | ca |
dc.subject.other | Tos ferina | ca |
dc.subject.other | Vacuna contra la tos ferina | ca |
dc.subject.other | Eficacia de la vacuna | ca |
dc.subject.other | Vigilancia hospitalaria | ca |
dc.subject.other | Tos ferina | ca |
dc.subject.other | Vacuna contra la tos ferina | ca |
dc.subject.other | Efectivitat de la vacuna | ca |
dc.subject.other | Vigilància hospitalària | ca |
dc.subject.other | Pertussis | ca |
dc.subject.other | Whooping cough | ca |
dc.subject.other | Pertussis vaccine | ca |
dc.subject.other | Vaccine effectiveness | ca |
dc.subject.other | Hospital surveillance | ca |
dc.title | Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019 | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.identifier.doi | https://dx.doi.org/10.1016/j.vaccine.2024.02.090 | ca |